Pleconaril
Phase 2Small molecule
Merck & Co.Pleconaril is one of 54 small molecule programs targeting Common Cold. It is currently in Phase 2.
2
Indications
2
Total Trials
0
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
308 competitors in Sepsis
#DrugCompanyPhaseTrials
1Corlanor
AmgenPreclinical
Simdax
Orion Corporation, Orion PharmaPreclinical
Zyvox
PfizerPreclinical
Zemplar
AbbViePreclinical
Primaxin
PfizerPreclinical
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Levophed
GGeneral Hospital of Ningxia Medical University
Preclinical
Pleconaril
Merck & Co.Phase 2
Epsom Salt
FFresenius Kabi Oncology Ltd.
Preclinical
Aquasol a
BBandim Health Project
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Common Cold1 trial
Sepsis1 trial
Pleconaril Enteroviral Sepsis Syndrome
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00031512·61 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pleconaril. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company